Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 10/2016

04.01.2016 | Otology

Acetazolamide in vestibular migraine prophylaxis: a retrospective study

verfasst von: Neşe Çelebisoy, Figen Gökçay, Ceyda Karahan, Cem Bilgen, Tayfun Kirazlı, Hale Karapolat, Timur Köse

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to check the efficacy of acetazolamide in the prophylaxis of vestibular migraine (VM). Treatment options in VM are mainly based on migraine guidelines. We tried to assess the efficacy of acetazolamide in these patients depending on clinical similarities with episodic ataxia type 2 and familial hemiplegic migraine responding to the drug. This is a retrospective cohort study. Among 50 patients with VM and prescribed acetazolamide 500 mg/day, 39 patients were studied as five had been lost on follow-up and six had stopped taking the drug due to side effects. Vertigo and headache frequency determined by number of attacks per month, and the severity determined by visual analog scales measured in centimeters from 0 to 10 were collected from the records. Initial reported figures for frequency and severity were compared with the results gathered after 3 months of treatment. The results were compared. Acetazolamide was effective in reducing both the frequency and severity of vertigo and headache attacks and this effect was more prominent for vertigo frequency and severity.
Literatur
1.
3.
Zurück zum Zitat Cass SP, Furman JM, Ankerstjerne K, Balaban C, Yetişer S, Aydogan B (1997) Migraine-related vestibulopathy. Ann Otol Rhinol Laryngol 106:182–189CrossRefPubMed Cass SP, Furman JM, Ankerstjerne K, Balaban C, Yetişer S, Aydogan B (1997) Migraine-related vestibulopathy. Ann Otol Rhinol Laryngol 106:182–189CrossRefPubMed
4.
5.
Zurück zum Zitat Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo and migrainous vertigo. Neurology 56:436–441CrossRefPubMed Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo and migrainous vertigo. Neurology 56:436–441CrossRefPubMed
6.
Zurück zum Zitat Reploeg MD, Goebel JA (2002) Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 23:364–371CrossRefPubMed Reploeg MD, Goebel JA (2002) Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 23:364–371CrossRefPubMed
7.
Zurück zum Zitat Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D (2012) Vestibular migraine: diagnostic criteria. J Vest Res 22:167–172 Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D (2012) Vestibular migraine: diagnostic criteria. J Vest Res 22:167–172
8.
Zurück zum Zitat International Headache Society Classification Subcommittee (2013) The International Classification of Headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef International Headache Society Classification Subcommittee (2013) The International Classification of Headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
9.
Zurück zum Zitat Neuhauser H, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T, Lempert T (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67:1028–1033CrossRefPubMed Neuhauser H, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T, Lempert T (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67:1028–1033CrossRefPubMed
10.
Zurück zum Zitat Neff BA, Staab JP, Eggers SD, Carlson ML, Schmitt WR, Van Abel KM, Worthington DK, Beatty CW, Driscoll CL, Shepard NT (2012) Auditory and vestibular symptoms and chronic subjective dizziness in patients with Meniere’s disease, vestibular migraine and Meniere’s disease with concomitant vestibular migraine. Otol Neurotol 33:1235–1244CrossRefPubMed Neff BA, Staab JP, Eggers SD, Carlson ML, Schmitt WR, Van Abel KM, Worthington DK, Beatty CW, Driscoll CL, Shepard NT (2012) Auditory and vestibular symptoms and chronic subjective dizziness in patients with Meniere’s disease, vestibular migraine and Meniere’s disease with concomitant vestibular migraine. Otol Neurotol 33:1235–1244CrossRefPubMed
11.
Zurück zum Zitat Radtke A, von Brevern M, Neuhauser H, Hottenrott T, Lempert T (2012) Vestibular migraine: long term follow-up of clinical symptoms and vestibulo-cochlear findings. Neurology 79:1607–1614CrossRefPubMed Radtke A, von Brevern M, Neuhauser H, Hottenrott T, Lempert T (2012) Vestibular migraine: long term follow-up of clinical symptoms and vestibulo-cochlear findings. Neurology 79:1607–1614CrossRefPubMed
12.
Zurück zum Zitat Celebisoy N, Gökçay F, Sirin H, Bıçak N (2008) Migrainous vertigo: clinical, oculographic and posturographic findings. Cephalalgia 28:72–77PubMed Celebisoy N, Gökçay F, Sirin H, Bıçak N (2008) Migrainous vertigo: clinical, oculographic and posturographic findings. Cephalalgia 28:72–77PubMed
13.
Zurück zum Zitat Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543–552CrossRefPubMed Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543–552CrossRefPubMed
14.
Zurück zum Zitat Von Brevern M, Ta N, Shankar A, Wieste A, Siegel A, Radtke A, Sander T, Escayg A (2006) Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4. Headache 46(1136–1):141 Von Brevern M, Ta N, Shankar A, Wieste A, Siegel A, Radtke A, Sander T, Escayg A (2006) Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4. Headache 46(1136–1):141
15.
Zurück zum Zitat Kim JS, Yue Q, Jen JC, Nelson SF, Baloh RW (1998) Familial migraine with vertigo: no mutations found in CACNA1A. Am J Med Gen 79:148–151CrossRef Kim JS, Yue Q, Jen JC, Nelson SF, Baloh RW (1998) Familial migraine with vertigo: no mutations found in CACNA1A. Am J Med Gen 79:148–151CrossRef
16.
Zurück zum Zitat Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A (2014) Flunarizine in the prophylaxis of migrainous vertigo. Eur Arch Otorhinolaryngol 271:2931–2936CrossRefPubMed Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A (2014) Flunarizine in the prophylaxis of migrainous vertigo. Eur Arch Otorhinolaryngol 271:2931–2936CrossRefPubMed
17.
Zurück zum Zitat Bikhazi P, Jackson C, Ruckenstein MJ (1997) Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 18:350–354PubMed Bikhazi P, Jackson C, Ruckenstein MJ (1997) Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 18:350–354PubMed
18.
Zurück zum Zitat Maione A (2006) Migraine-related vertigo: diagnostic criteria and prophylactic treatment. Laryngoscope 116:1782–1786CrossRefPubMed Maione A (2006) Migraine-related vertigo: diagnostic criteria and prophylactic treatment. Laryngoscope 116:1782–1786CrossRefPubMed
19.
Zurück zum Zitat Baier B, Winkenwerder E, Dieterich M (2009) “Vestibular migraine”: effects of prophylactic therapy with various drugs. A retrospective study. J Neurol 256:436–442CrossRefPubMed Baier B, Winkenwerder E, Dieterich M (2009) “Vestibular migraine”: effects of prophylactic therapy with various drugs. A retrospective study. J Neurol 256:436–442CrossRefPubMed
20.
Zurück zum Zitat Bisdorff AR (2004) Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2:103–108PubMed Bisdorff AR (2004) Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2:103–108PubMed
21.
Zurück zum Zitat Gode S, Celebisoy N, Kirazli T, Akyuz A, Bilgen C, Karapolat H, Sirin H, Gokcay F (2010) Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 50:77–84CrossRefPubMed Gode S, Celebisoy N, Kirazli T, Akyuz A, Bilgen C, Karapolat H, Sirin H, Gokcay F (2010) Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 50:77–84CrossRefPubMed
22.
Zurück zum Zitat Taghdiri F, Togha M, Jahromi SR, Refaeian F (2014) Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus 3:231–235CrossRefPubMedPubMedCentral Taghdiri F, Togha M, Jahromi SR, Refaeian F (2014) Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. Springerplus 3:231–235CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kohshi K, Konda N, Kinoshita Y, Tsuru E, Yokota A (1994) In situ arterial and brain tissue PCO2 responses to acetazolamide in cats. J Appl Physiol 76:2199–2203PubMed Kohshi K, Konda N, Kinoshita Y, Tsuru E, Yokota A (1994) In situ arterial and brain tissue PCO2 responses to acetazolamide in cats. J Appl Physiol 76:2199–2203PubMed
24.
Zurück zum Zitat Aggarwal M, Kondeti B, McKenna R (2013) Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 23:717–724CrossRefPubMed Aggarwal M, Kondeti B, McKenna R (2013) Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 23:717–724CrossRefPubMed
25.
Zurück zum Zitat De Simone R, Marano E, Di Stasio E, Bonuso S, Fiorillo C, Bonavita V (2005) Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache 45:385–386CrossRefPubMed De Simone R, Marano E, Di Stasio E, Bonuso S, Fiorillo C, Bonavita V (2005) Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache 45:385–386CrossRefPubMed
26.
Zurück zum Zitat Robbins MS, Lipton RB, Laureta EC, Grosberg BM (2009) CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2. Headache 49:1042–1046CrossRefPubMed Robbins MS, Lipton RB, Laureta EC, Grosberg BM (2009) CACNA1A nonsense mutation is associated with basilar-type migraine and episodic ataxia type 2. Headache 49:1042–1046CrossRefPubMed
27.
Zurück zum Zitat Tricarico D, Barbieri MG, Conte Camerino D (2000) Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 48:304–312CrossRefPubMed Tricarico D, Barbieri MG, Conte Camerino D (2000) Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 48:304–312CrossRefPubMed
28.
Zurück zum Zitat Omata T, Takanashi J, Wada T, Arai H, Tanabe Y (2011) Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain Dev 33:332–334CrossRefPubMed Omata T, Takanashi J, Wada T, Arai H, Tanabe Y (2011) Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain Dev 33:332–334CrossRefPubMed
29.
Zurück zum Zitat Shirai T, Meyer JS, Akiyama H, Mortel KF, Wills PM (1996) Acetazolamide testing of cerebral vasodilator capacity provokes ‘vascular’ but not tension headaches. Headache 36:589–594CrossRefPubMed Shirai T, Meyer JS, Akiyama H, Mortel KF, Wills PM (1996) Acetazolamide testing of cerebral vasodilator capacity provokes ‘vascular’ but not tension headaches. Headache 36:589–594CrossRefPubMed
30.
Zurück zum Zitat Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 16:968–981CrossRefPubMed Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 16:968–981CrossRefPubMed
31.
Zurück zum Zitat Loder E, Burch R, Rizzoli P (2012) The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 52:930–945CrossRefPubMed Loder E, Burch R, Rizzoli P (2012) The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 52:930–945CrossRefPubMed
32.
Zurück zum Zitat Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults (review). Cochrane Database Syst Rev 6:1–58 Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults (review). Cochrane Database Syst Rev 6:1–58
33.
Zurück zum Zitat Baloh RW, Foster CA, Yue Q, Nelson SF (1996) Familial migraine with vertigo and essential tremor. Neurology 46:458–460CrossRefPubMed Baloh RW, Foster CA, Yue Q, Nelson SF (1996) Familial migraine with vertigo and essential tremor. Neurology 46:458–460CrossRefPubMed
Metadaten
Titel
Acetazolamide in vestibular migraine prophylaxis: a retrospective study
verfasst von
Neşe Çelebisoy
Figen Gökçay
Ceyda Karahan
Cem Bilgen
Tayfun Kirazlı
Hale Karapolat
Timur Köse
Publikationsdatum
04.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 10/2016
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-015-3874-4

Weitere Artikel der Ausgabe 10/2016

European Archives of Oto-Rhino-Laryngology 10/2016 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.